Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Inspire Medical Systems (INSP)

Inspire Medical Systems Q3 revenue rises 33% to $203.2 million; raises EPS guidance

Positive Impact 4 of 5 earnings Written later

Inspire Medical Systems reported third-quarter 2024 revenue of $203.2 million, up 33% from $153.3 million a year earlier, and diluted earnings per share of $0.60 compared with a loss of $0.29 per share in the prior-year quarter. The company raised its full-year 2024 revenue guidance to $793 million to $798 million from $788 million to $798 million, and raised its full-year diluted EPS guidance to $1.20 to $1.40 from $0.60 to $0.80.

Key points

  • Q3 2024 revenue $203.2 million, up 33% year over year; U.S. revenue $195.8 million
  • Q3 2024 net income $18.5 million; diluted EPS $0.60 versus a diluted net loss of $0.29 per share in Q3 2023
  • Full-year 2024 revenue guidance raised to $793 million to $798 million; EPS guidance raised to $1.20 to $1.40
  • Full-year 2024 gross margin guidance maintained at 83% to 85%

The filing

CompanyInspire Medical Systems (INSP)
Form8-K, current report
Filed with the SECNov 4, 2024, 4:03 PM ET
Accession number0001609550-24-000050

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:55 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.